PROF logo

Profound Medical Corp. (PROF)

$7.34

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PROF

Market cap

$267464247

EPS

1.4

P/E ratio

118.2

Price to sales

15.97

Dividend yield

--

Beta

0.788361

Price on PROF

Previous close

$7.42

Today's open

$7.42

Day's range

$7.14 - $7.42

52 week range

$4.80 - $8.95

Profile about PROF

CEO

Arun Menawat

Employees

131

Headquarters

Mississauga, ON

Exchange

NASDAQ Capital Market

Shares outstanding

36626844

Issue type

Common Stock

PROF industries and sectors

Healthcare

Medical Equipment & Supplies

News on PROF

Profound Medical to Participate in the Stifel 2026 Healthcare Conference

TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC.

news source

GlobeNewsWire • Nov 9, 2026

news preview

What Profound Medical (PROF) Said on Its Q3 Earnings Call

Profound Medical NASDAQ: PROF reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned leadership transition.

news source

MarketBeat • Nov 6, 2026

news preview

Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy?

Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates

Profound Medical (PROF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or higher New Cook Medical agreement positions TULSA-PRO ® within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach across the United States Richard Fabian appointed as CEO, effective January 14, 2027; Arun Menawat to transition to Executive Chairman; Matthew Sobczyk becomes permanent CFO; Jason Mills joins Board TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

news source

GlobeNewsWire • Nov 5, 2026

news preview

Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach

news source

GlobeNewsWire • Oct 30, 2026

news preview

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next  Let's Huddle webinar for a discussion with its host, Leonard Wheeler, on November 5, 2026, at 3:00 p.m. ET. Mr. Williams will share his personal perspectives on health advocacy, resilience, informed healthcare decisions and the importance of protecting quality of life.

news source

GlobeNewsWire • Oct 22, 2026

news preview

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ® system.

news source

GlobeNewsWire • Oct 14, 2026

news preview

Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Oct 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Profound Medical Corp.

Open an M1 investment account to buy and sell Profound Medical Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PROF on M1